First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference
May 15 2023 - 07:00AM
First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma”
or the “Company”), a clinical-stage biopharmaceutical company
specializing in the development of targeted, non-systemic therapies
for gastrointestinal (GI) diseases, announced today that James
Sapirstein, Chief Executive Officer of First Wave BioPharma, will
present at the 2023 BIO International Conference on Tuesday, June 6
11:45 AM in Room 104A. The conference is taking place June 5-8 in
the Boston Convention & Exhibition Center in Boston,
Massachusetts.
Details of the event are as follows:
Event: |
2023 BIO International Conference |
Date: |
Tuesday, June 6, 2023 |
Time: |
11:45 a.m. ET |
Location: |
Room 104A |
Registration: |
https://www.bio.org/events/bio-international-convention |
Mr. Sapirstein will provide an overview of First Wave
BioPharma’s business and clinical development programs and discuss
anticipated 2023 milestones.
Additionally, Mr. Sapirstein and members of the First Wave
BioPharma management team will be participating in virtual
one-on-one partnering meetings with pharmaceutical company
executives and registered investors.
About First Wave BioPharma, Inc.First Wave
BioPharma is a clinical-stage biopharmaceutical company
specializing in the development of targeted, non-systemic therapies
for gastrointestinal (GI) diseases. The Company is currently
advancing a therapeutic development pipeline with multiple clinical
stage programs built around its two proprietary technologies – the
biologic adrulipase, a recombinant lipase enzyme designed to enable
the digestion of fats and other nutrients, and niclosamide, an oral
small molecule with anti-inflammatory properties. First Wave is
advancing two Phase 2 clinical programs built around adrulipase for
the treatment of exocrine pancreatic insufficiency (FW-EPI) in
patients with cystic fibrosis (CF) and chronic pancreatitis (CP).
In developing adrulipase, First Wave is seeking to provide CF and
CP patients with a safe and effective therapy to control EPI that
is non-animal derived and offers the potential to dramatically
reduce their daily pill burden. The company is also advancing
multiple programs involving niclosamide, including FW-UP for
ulcerative proctitis and ulcerative proctosigmoiditis, FW-UC for
ulcerative colitis, and FW-CD for Crohn’s disease. First Wave
BioPharma is headquartered in Boca Raton, Florida. For more
information visit www.firstwavebio.com.
Forward-Looking StatementsThis press release
may contain certain statements relating to future results which are
forward-looking statements. It is possible that the Company’s
actual results and financial condition may differ, possibly
materially, from the anticipated results and financial condition
indicated in these forward-looking statements, depending on factors
including whether results obtained in preclinical and nonclinical
studies and clinical trials will be indicative of results obtained
in future clinical trials; whether preliminary or interim results
from a clinical trial will be indicative of the final results of
the trial; whether the Company will be able to maintain compliance
with Nasdaq’s continued listing criteria and the effect of a
delisting from Nasdaq on the market for the Company’s securities;
the size of the potential markets for the Company’s drug candidates
and its ability to service those markets; the effects of the First
Wave Bio, Inc. acquisition, the related settlement and their effect
on the Company’s business, operating results and financial
prospects; and the Company’s current and future capital
requirements and its ability to raise additional funds to satisfy
its capital needs. Additional information concerning the Company
and its business, including a discussion of factors that could
materially affect the Company’s financial results are contained in
the Company’s Annual Report on Form 10-K for the year ended
December 31, 2022 under the heading “Risk Factors,” as well as the
Company’s subsequent filings with the Securities and Exchange
Commission. All forward-looking statements included in this press
release are made only as of the date of this press release, and we
do not undertake any obligation to publicly update or correct any
forward-looking statements to reflect events or circumstances that
subsequently occur or of which we hereafter become aware.
For more information:First Wave BioPharma,
Inc.777 Yamato Road, Suite 502Boca Raton, FL 33431Phone: (561)
589-7020info@firstwavebio.compartnering@firstwavebio.com
First Wave BioPharma (NASDAQ:FWBI)
Historical Stock Chart
From Feb 2024 to Mar 2024
First Wave BioPharma (NASDAQ:FWBI)
Historical Stock Chart
From Mar 2023 to Mar 2024